Dyadic Prices $2.9M Registered Direct Offering with Warrants at $0.795/Share
DYAI sits 18% above its 52-week low of $0.655.
Summary
Dyadic International secured $2.9 million through a registered direct offering and concurrent private placement, pricing shares at $0.795 with warrants exercisable at $0.84. The deal includes standstill and lock-up restrictions, and registration rights for warrant shares.
Key Events · Financing and Capital Events · DYAI
-
Registered Direct Offering Priced
Dyadic agreed to sell 3,625,000 shares at $0.795 per share, raising approximately $2.9 million in gross proceeds before expenses.
-
Concurrent Warrant Issuance
Investors received warrants to purchase 3,625,000 shares at $0.84 per share, with a five-year term and a purchase price of $0.005 per warrant.
-
Standstill and Lock-Up Restrictions
The company agreed to a 90-day standstill on equity issuances and a 90-day lock-up for directors, officers, employees, and 10% shareholders.
-
Registration Rights Agreement
Dyadic must file a resale registration statement for the warrant shares within 30 days of closing, with penalties for delays.
Analysis · DYAI · Life Sciences
Dyadic International entered into definitive agreements for a $2.9 million registered direct offering and concurrent private placement. The offering includes 3,625,000 shares at $0.795 per share and warrants to purchase an equal number of shares at $0.84 per share. The warrants have a five-year term and were sold at $0.005 each. The company also agreed to a 90-day standstill on equity issuances, a 90-day lock-up for insiders, and registration rights for the warrant shares. This capital raise is critical for Dyadic, which recently disclosed a going concern warning with only $4.8 million in cash. The offering price is slightly above the current market price of $0.7702, indicating some investor demand despite the company's financial distress. The warrants provide additional potential dilution if exercised, but the immediate proceeds extend the company's cash runway.
At the time of this filing, DYAI was trading at $0.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.1M. The 52-week trading range was $0.65 to $1.60. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.